|Awarded On||February 21, 2018|
|Title||Development of an engineered & pharmacologically optimized human methionine-gamma-lyase drug candidate for the treatment of prostate cancer and glioblastoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Everett Stone|
|Cancer Sites||Brain and Other Nervous System, Prostate|
This proposal outlines the development of a novel biologic drug and an understanding of its mechanism of action that exploits a key defect observed in prostate cancer (PCa) and glioblastoma (GBM) metabolism; namely the extreme appetite that these cancers have for the amino acid methionine which fuels their growth. This demand is so great that radiolabeled methionine can be used to selectively image these tumors. The therapeutic we are developing depletes methionine from the blood and is selectively toxic to cancer cells as normal tissue does not have the same requirement for methionine. There is further evidence that methionine depletion keeps cancers from resisting the effects of standard o...